Clinical Edge Journal Scan

Disease burden is higher in women vs men with psoriatic arthritis


 

Key clinical point: The psoriatic arthritis (PsA) disease burden had worse impact on women vs men with PsA, with women having a higher disease activity, worse function, and greater disease burden.

Major finding: Female vs male patients with PsA had a significantly higher mean patient global assessment score ( P < .001), patient’s pain score ( P = .003 ), tender joint count ( P < .001), swollen joint count ( P = .033), and Disease Activity Score for PsA ( P < .001). Minimal disease activity was achieved by 44.0% of men vs 24.6% of women ( P = .003).

Study details: Findings are from a cross-sectional analysis of 2 longitudinal cohorts including 141 male and 131 female patients with PsA who received treatment with conventional synthetic or biologic disease-modifying antirheumatic drugs for at least 6 months.

Disclosures: This study did not receive funding. The authors declared no conflicts of interest.

Source: Lubrano E et al. Psoriatic arthritis in males and females: Differences and similarities. Rheumatol Ther. 2023 (Feb 16). Doi: 10.1007/s40744-023-00535-3

Recommended Reading

Psoriatic arthritis treatment for women falls short, study suggests
MDedge Rheumatology
Gender-based differences in treatment outcomes and persistence with ustekinumab or TNFi in PsA
MDedge Rheumatology
Achievement of low disease activity improves long-term structural damage in PsA
MDedge Rheumatology
Active disease in third trimester increases risk for emergency caesarean section in PsA
MDedge Rheumatology
Guselkumab resolves dactylitis and improves clinical outcomes in patients with active PsA
MDedge Rheumatology
JAKi effective for PsA but higher doses may have increased toxicity
MDedge Rheumatology
Real world study finds no evidence of increased cancer risk with JAKi vs TNFi in PsA
MDedge Rheumatology
Ultrasound helps screen patients with moderate-to-severe psoriasis progressing to subclinical PsA
MDedge Rheumatology
Concurrent onset of skin and joint symptoms tied to high disease activity in PsA
MDedge Rheumatology
Apremilast safe and effective in biologic-naive patients with early PsA
MDedge Rheumatology